A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer.

Oncotarget · 2017 · PMC5522041 · PMID 28410214

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantP < 0.01actually significant

We found a highly significant deficiency of C2ORF40 expression in all the breast cancer samples ( P < 0.01) (Figure 1C and 1D ), which was consistent with the qRT-PCR results.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.